IceCure Medical (ICCM) Registration Filing summary

Company overview and business model

• Commercial-stage medical device company specializing in cryoablation systems using liquid nitrogen for tumor treatment, offering minimally invasive alternatives to surgery for various tumor types including breast, lung, kidney, and bone.

• Lead product is the ProSense system and associated CryoProbes, with a focus on research, development, and marketing.

• Incorporated in Israel, with principal operations and R&D based in Caesarea, Israel, and subsidiaries in the US, Hong Kong, and China.

Financial performance and metrics

• As of June 30, 2025, cash and cash equivalents were $5.38 million actual and $12.70 million pro forma, reflecting recent rights offering and loan repayment.

• Total shareholders' equity was $2.89 million actual and $12.25 million pro forma.

• 68,699,415 Ordinary Shares issued and outstanding as of September 3, 2025.

• Rights offering in August 2025 raised $9.99 million in gross proceeds.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate and working capital purposes, including operations, capital expenditures, and R&D.

• Specific uses for each issuance will be detailed in the related prospectus supplement.